How China is leading the humanoid robots race
Psychologists now know exactly what makes someone cool. Turns out, the definitions are universal
3% mortgage rates aren't dead—housing market sees 127% increase in buyers taking over old loans
There's a reason your Sam's Club rotisserie chicken looks different
In the span of the last few years, China has overtaken the U.S. as the leader in the robotics race, especially when it comes to humanoid robots designed to mimic the human body and behavior. Earlier this year China literally raced robots against human counterparts, and they show no sign of slowing down.
While AI steals the investment and media spotlight, the competition for humanoid robotics supremacy has been quietly accelerating for 50 years, and we're now on the cusp of a momentous breakthrough. Mass-produced humanoid robots may reach us within the next 3–5 years, and the market is predicted to grow to $38B within just 10 years.
China is poised to capture the lion's share of this industry: Morgan Stanley found that 56% of robotics companies are already based there. However, this competition isn't just about market share—it's about industrial supremacy.
Fixed industrial robots now operate with productivity rates estimated to be 10 times that of humans, working almost 24/7 with virtually no errors. In this new era of free-moving humanoid robots, adaptable machines will navigate entire factory floors with equal precision and even higher productivity rates than their fixed (and human) counterparts.
American companies like Boston Dynamics are building impressive prototypes but those don't win industrial wars, production does. If the U.S. continues to lag behind in the robotics race, American businesses will face increased supply chain dependence on China and citizens could see wage stagnation and job losses to robotics leaders overseas.
I witnessed the U.S. lead the world in robotic advancements. Two of my humanoid robots went into space; one called 'Robonaut' now lives in the Smithsonian. Over the past decade, our momentum has slowed. To take back robotics supremacy, the U.S. must overcome four critical hurdles that could cost us this race.
Yes, Chinese robotics startups are benefiting from established supply chains, local adoption opportunities, and strong national government support, but nagging domestic problems are holding the United States back, regardless of any other country's advancements.
First, we're battling our own cultural fears. There's a prevailing anxiety that robots will replace human jobs, particularly in factories. While massive change in manufacturing is fast approaching, the fear of replacement is not only wrong—it's counterproductive. Humanoid robots excel at 'dirty, dark, and dangerous' jobs that often lack willing human labor anyway.
To overcome U.S. cultural fears around robotics, we must think of robots not as standing in our place but standing by our sides. WWII was won as much on the mechanized manufacturing floor as on the battlefield and novel machines were essential to winning the space race. When Robonaut shook hands with a fellow astronaut aboard the International Space Station, it was proof that robots can and should support human work, not compete with it.
Second, we're not cultivating the people behind the humanoids. The real challenge in winning the humanoid race isn't job displacement; it's the massive lack of skilled domestic workers to develop, operate, and maintain advanced robotics. At Texas A&M, I teach brilliant students ready to tackle real-world problems with robots. Educating the workforce about how to leverage robots will empower the next generation and dispel fear. However, across the country, preparation for careers in STEM is lacking. We need more accessible science programs, apprenticeships, and pathways into robotics now.
Third, the economics still intimidate us. Developing humanoid robots involves significant upfront costs and still faces expensive technical hurdles, including improving spatial awareness and task adaptability. But here's what the bean counters are missing: once mass production kicks in, the cost of robot labor could plummet from $10 to just $0.25 per hour in as little as 10 years. The industry will transform overnight and whichever country controls this shift owns the future of manufacturing. Focusing on the future affordability of robot labor will incentivize both the private and public sector to invest now.
Fourth, our policy framework is falling behind. While the U.S. offers some incentives for research and innovation, they pale in comparison to China's commitment. The Chinese government has poured over $20 billion into robotics and next-generation technologies, providing subsidies for startups and covering costs for equipment and talent acquisition. They're projected to match U.S. robotics research and development levels by 2034.
Meanwhile, current U.S. tax code continues to disincentivize longer-term innovation projects by forcing companies to pay more up front for R&D. As the U.S. federal government increasingly overlaps its ambitions with AI tech companies, so too must it champion the development of humanoid robots as a national security and productivity imperative.
In tandem with overcoming these inherent challenges, the U.S. must seize two unique opportunities that offer a high return on investment and a clear path to victory.
Humanoid robots can maintain our edge in advanced manufacturing. Humanoids integrated with AI and embedded into the internet of things will create smart factories that enhance precision, improve product quality, and accelerate production times. The U.S. currently leads the world in the development of smart textiles—humanoid robots could accelerate production to maintain this advantage.
Warehouses offer an arena for rapid humanoid adoption. The number of warehouses across the U.S. continues to expand, with Amazon recently announcing plans for dozens more across rural areas. Our vast network of warehouses is primed for humanoid robots to revolutionize its operations by automating sorting, packing, and transport alongside humans to boost efficiency and slash costs.
These aren't theoretical applications: they're already being tested at sites like BMW's South Carolina plant, where robotics partners are deployed for logistics and warehousing tasks.
These deployments leverage our existing strengths in technology and innovation while addressing real, immediate market needs. We don't need to wait for the perfect humanoid robot—we can start dominating these sectors today and build from there.
This race not just about machines; it's about maintaining U.S. leadership in technology, safety, and industrial strength. If we want the next generation of robotics to serve American interests, we must act now or be left standing on the sidelines of the next industrial revolution.
During my two decades at NASA, I saw what American innovators can achieve when given a mission. We sent robots to the Moon, Mars, and into orbit—not because it was easy, but because we believed it mattered for future generations. That same spirit must drive our investment in humanoid robotics today so we can cross the finish line first tomorrow.
This post originally appeared at fastcompany.comSubscribe to get the Fast Company newsletter: http://fastcompany.com/newsletters
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Celebrating the Future of Accounting - One Student at a Time
London School of Business & Finance Singapore Campus Recognised as ISCA Registered Learning Organisation SINGAPORE, July 7, 2025 /PRNewswire/ -- At the ISCA SCAQ Top Achievers & Partners Recognition Ceremony held on 13 May 2025, LSBF Singapore was recognised as an ISCA Registered Learning Organisation. The event brought together leading voices in the profession to celebrate the outstanding achievements of students in the Singapore Chartered Accountant Qualification (SCAQ) programme — and to honour the education partners shaping their journey. This recognition is more than a badge of honour — it's a reflection of LSBF's belief in the power of education, mentorship, and hands-on experience to transform aspiring accountants into confident, future-ready professionals. "We're deeply invested in the growth of our learners," said Yvonne Goh, Head of School of Professional Education, LSBF Singapore. "Whether in the classroom or through real-world exposure, our goal is to equip them not just with technical skills, but with the mindset to lead in a fast-changing world." Mr David Yeong, Head of ISCA Academy, said, "At ISCA, we believe that shaping the next generation of Chartered Accountants requires strong partnerships with Registered Learning Organisations (RLOs) who share our commitment of innovation and excellence. LSBF Singapore exemplifies this spirit through innovative teaching and dedicated support for students pursuing the SCAQ. We look forward to working together to nurture future Chartered Accountants and advancement of the accountancy profession." LSBF's SCAQ tutors, who joined the celebration, continue to play a vital role in delivering rigorous, relevant, and inspiring learning experiences. Together, LSBF is proud to support a new generation of Chartered Accountants who will drive progress in the industry. About London School of Business & Finance (LSBF) The London School of Business & Finance (LSBF), founded in 2003 and a member of the Global University System (GUS), serves over 25,000 students across more than 40 countries. With campuses in key cities including the UK, Singapore, and Malaysia, LSBF has expanded its international footprint, particularly in Asia. LSBF Singapore campus offers over 100 programmes in business, finance, law, hospitality, and technology, and collaborate with reputable universities to provide internationally recognised qualifications. LSBF holds EduTrust certification, partners with organizations like Grab, Deloitte and ISCA, and is an ACCA Approved Learning Partner. In recognition of its future-focused approach to education, LSBF was honoured with the Singapore Business Review's International Business Award in Education for two consecutive years – 2024 and 2025. These accolades reaffirm LSBF's commitment to delivering quality, industry-aligned education that empowers aspiring professionals globally. View original content to download multimedia: SOURCE London School of Business & Finance Singapore Campus Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
Workers union announces tentative agreement with King Soopers after days of negotiations
The union that represents thousands of Colorado King Soopers employees announced on Thursday it had reached a tentative agreement on a three-year contract with the company after days of negotiations.

Yahoo
7 minutes ago
- Yahoo
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
Court denies Vivo Capital's petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li BEIJING, July 07, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that on June 30, the United States District Court for the District of Massachusetts denied Vivo Capital's petition against 1Globe Capital LLC ("1Globe") for relief relating to SINOVAC's shareholder votes and corporate governance. In its ruling, the Court concluded, "relief relating to governance outcomes or shareholder votes – are DENIED without prejudice." The Massachusetts ruling marks the fourth unsuccessful legal attempt by either Advantech/Prime Success ("Advantech/Prime") or Vivo Capital (together "the Dissenting Investor Group") to strip SINOVAC common shareholders of their rightful dividend payments. This result follows Advantech/Prime's recently failed petition in New York and Advantech/Prime and Vivo Capital's recently failed petition in Hong Kong – which were repeated attempts to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the Company's payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. The Dissenting Investor Group continues to interfere with the current Board's fiduciary duties to implement the UK Privy Council's unappealable ruling in January 2025. In this ruling, the UK Privy Council deemed the former illegitimate board an "Imposter Board" and handed 1Globe – the investment arm of a cancer-focused global R&D group and SINOVAC's largest shareholder – a victory on all grounds. In addition, the UK Privy Council Judicial Committee, comprising five UK Supreme Court Justices, concluded that there was "nothing unlawful in the conduct of 1Globe" in connection with SINOVAC's 2018 AGM. The Dissenting Investor Group's self-serving, multi-pronged lawfare strategy is crystal clear: (1) block actions taken by the SINOVAC Board to distribute rightful dividend payments to valid SINOVAC common shareholders; (2) protect the ill-gotten gains it stripped from SINOVAC subsidiaries over the past seven years; and (3) regain control of SINOVAC in order to continue to loot the Company. Having failed in the courtroom, the Dissenting Investor Group has decided to instead use deceptive and false stories to attack 1Globe and its founder Dr. Chiang Li, who chairs the current SINOVAC Board. As noted in SINOVAC's proxy materials, Dr. Li is an accomplished clinician, scientist, inventor, entrepreneur and a seasoned executive with international recognitions. Dr. Li and 1Globe have successfully challenged the Dissenting Investor Group's abuse in court for the past seven years and championed the rights and interests of all valid SINOVAC shareholders. During those seven years, The Dissenting Investor Group, in coordination with the former illegitimate board (the "Imposter Former Board"), pursued the following schemes: Privatization attempt at a below-market price in 2016, which would have succeeded had it not been for the efforts of 1Globe (who declined an invite by the Former Management Buyout Group to join and profit from its privatization attempt); Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; Commitment by the Imposter Former Board to invest ~US$139 million of SINOVAC cash into a venture fund managed by Vivo Capital – creating a clear conflict of interest. This would be in addition to the approximately US$100 million SINOVAC has already invested into Vivo Capital funds. US$15 million debt investment into Sinovac Life Sciences Co., Ltd. ("SLS"), a wholly owned subsidiary of SINOVAC, in exchange for a 15% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$1 billion of distributions made to the Dissenting Investor Group. In contrast, SINOVAC common shareholders have received no dividends and haven't been able to trade their shares for the past six years. To add insult to injury, the Imposter Former Board publicly stated in April 2024 in the Company's 2023 20-F that it had "no plan to pay any cash dividends on SINOVAC Antigua's shares in the foreseeable future"; Barrage of baseless and wasteful legal action in 2025, after refusing to accept the Privy Council's non-appealable ruling, with the goal of interfering with the dividend payment unless the Dissenting Investor Group is able to double dip on dividends already received from SLS; Deceptive and disparaging campaign against current SINOVAC board members that is meant to intimidate them and interfere with the stability and function of the current Board. The Dissenting Investor Group's hostile actions, baseless claims and wasteful litigation are evidence that it poses a direct threat to the value of your investment and the future of SINOVAC. Don't let the Dissenting Investor Group, which is working in coordination with SAIF and is represented on SAIF's Reconstituted Imposter Former Board, regain control of the Company. If the Reconstituted Imposter Former Board succeeds, it will put all valid shareholders' future dividend payments at risk – this includes the current Board's announced plans for an additional US$11.00 per common share cash dividend, contingent on the cancellation of the unauthorized PIPE shares, and its adopted policy to issue regular dividends out of surplus cash. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card "AGAINST" Proposal 1 to remove the current Board and "AGAINST" Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data